BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) (FRA:NPAU) announced it had appointed The Conscience Fund’s founder Henri Sant-Cassia to its board of directors.
Sant-Cassia is a founding partner of The Conscious Fund, a US$60 million fund that is one of the most active venture funds in the field of psychedelic medicine.
The new board member has 10 years of experience in the plant-based medicine field and has helped create over $200 million in company valuations within the psychedelic sector.
READ: BetterLife Pharma to raise up to C$2.6M in a public equity offering
“We are extremely pleased to welcome Henri Sant-Cassia to our Board of Directors. He brings a wealth of experience in the psychedelic space, which will be very valuable as we execute our plans to develop non-hallucinogenic compounds to treat depression and other mental health disorders,” BetterLife CEO Ahmad Doroudian said in a statement.
“We look forward to working with The Conscious Fund team and their extensive network within the psychedelic community.”
Sant-Cassia added: "I am delighted to be working with Ahmad, who is one of the new breeds of CEOs from the bioscience space, and Patrick, one of the longest serving members of the psychedelic medicine community. We believe that BetterLife has enormous untapped potential, both within second generation psychedelic therapies and in the wider medical field.”
BetterLife also announced that Sergei Stetenko has resigned from its board of directors.
Vancouver-based BetterLife is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas